Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelLBxHealth's revenue for the
six
months ended in Jun. 2026 was $0.80 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $1.54 Mil.
CelLBxHealth's Revenue per Share for the
six
months ended in Jun. 2026 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00.
Warning Sign:
CelLBxHealth PLC revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of CelLBxHealth was -62.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 10.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, CelLBxHealth's highest 3-Year average Revenue per Share Growth Rate was 35.70% per year. The lowest was -40.20% per year. And the median was -13.30% per year.
CelLBxHealth (OTCPK:ANPCF) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
CelLBxHealth Revenue Related Terms
CelLBxHealth Revenue Historical Data
* Premium members only.
The historical data trend for CelLBxHealth's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, CelLBxHealth's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CelLBxHealth Revenue vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's Revenue distribution charts can be found below:
* The bar in red indicates where CelLBxHealth's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CelLBxHealth (ANPCF) has a Revenue of $1.54 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on CelLBxHealth and its competitors.
Is CelLBxHealth's Revenue too high?
CelLBxHealth's current Revenue is $1.54 Mil.
How does CelLBxHealth's Revenue compare to TMO and DHR?
CelLBxHealth's Revenue of $1.54 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Diagnostics & Research company?
A good Revenue depends on the Medical Diagnostics & Research industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on CelLBxHealth and its competitors. CelLBxHealth's current Revenue is $1.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
CelLBxHealth (ANPCF) has a current Revenue of $1.54 Mil. The current Revenue is $1.54 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For CelLBxHealth (ANPCF), the current Revenue is $1.54 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANPCF has been successfully added to your 
